About InFlectis BioScience
InFlectis BioScience is a company based in Nantes (France) founded in 2013 by Philippe GuEdat and Pierre Miniou.. InFlectis BioScience has raised $8.76 million across 2 funding rounds from investors including GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity. InFlectis BioScience offers products and services including Small Molecule Therapeutics. InFlectis BioScience operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Nantes, France
- Founders Philippe GuEdat, Pierre Miniou
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.76 M (USD)
in 2 rounds
-
Latest Funding Round
$6.68 M (USD), Series A
Jun 01, 2016
-
Investors
GO CAPITAL
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InFlectis BioScience
InFlectis BioScience offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops brain-penetrant molecules for treating neurological diseases
Funding Insights of InFlectis BioScience
InFlectis BioScience has successfully raised a total of $8.76M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.68 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $6.7M
-
First Round
First Round
(13 Jan 2015)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2016 | Amount | Series A - InFlectis BioScience | Valuation | Credit Mutuel Equity | |
| Jan, 2015 | Amount | Seed - InFlectis BioScience | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in InFlectis BioScience
InFlectis BioScience has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Remiges Ventures is engaged in biotech venture capital investments.
|
Founded Year | Domain | Location | |
|
Private equity investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by InFlectis BioScience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - InFlectis BioScience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inflectis Bioscience Comparisons
Competitors of InFlectis BioScience
InFlectis BioScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for rare and orphan diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inflectis Bioscience
Frequently Asked Questions about InFlectis BioScience
When was InFlectis BioScience founded?
InFlectis BioScience was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is InFlectis BioScience located?
InFlectis BioScience is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
Who is the current CEO of InFlectis BioScience?
Philippe GuEdat is the current CEO of InFlectis BioScience. They have also founded this company.
Is InFlectis BioScience a funded company?
InFlectis BioScience is a funded company, having raised a total of $8.76M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.07M, raised on Jan 13, 2015.
What does InFlectis BioScience do?
InFlectis BioScience was founded in 2013 in Nantes, France, within the biotechnology sector. Small molecule drugs are developed to target cellular mechanisms against misfolded proteins, focusing on neurodegenerative and orphan diseases. Lead programs address Charcot-Marie-Tooth and Retinitis Pigmentosa. IFB-088 modulates the UbiquitinProteasome System via the PP1PPP1R15A interaction, while IFB-008 is advanced for related retinal and neurodegenerative conditions.
Who are the top competitors of InFlectis BioScience?
InFlectis BioScience's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does InFlectis BioScience offer?
InFlectis BioScience offers Small Molecule Therapeutics.
Who are InFlectis BioScience's investors?
InFlectis BioScience has 3 investors. Key investors include GO CAPITAL, Remiges Ventures, and Crédit Mutuel Equity.